[go: up one dir, main page]

PL1794327T3 - Niezależna od szczepu amplifikacja patogenów i szczepionki przeciwko nim - Google Patents

Niezależna od szczepu amplifikacja patogenów i szczepionki przeciwko nim

Info

Publication number
PL1794327T3
PL1794327T3 PL05797971T PL05797971T PL1794327T3 PL 1794327 T3 PL1794327 T3 PL 1794327T3 PL 05797971 T PL05797971 T PL 05797971T PL 05797971 T PL05797971 T PL 05797971T PL 1794327 T3 PL1794327 T3 PL 1794327T3
Authority
PL
Poland
Prior art keywords
vaccines
pathogens
independent amplification
strain independent
strain
Prior art date
Application number
PL05797971T
Other languages
English (en)
Inventor
Charles Nicolette
Irina Tcherepanova
Jason Harris
Donald Healey
Original Assignee
Argos Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argos Therapeutics, Inc. filed Critical Argos Therapeutics, Inc.
Publication of PL1794327T3 publication Critical patent/PL1794327T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL05797971T 2004-09-14 2005-09-14 Niezależna od szczepu amplifikacja patogenów i szczepionki przeciwko nim PL1794327T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52231004P 2004-09-14 2004-09-14
US66513005P 2005-03-25 2005-03-25

Publications (1)

Publication Number Publication Date
PL1794327T3 true PL1794327T3 (pl) 2017-04-28

Family

ID=36060671

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05797971T PL1794327T3 (pl) 2004-09-14 2005-09-14 Niezależna od szczepu amplifikacja patogenów i szczepionki przeciwko nim

Country Status (11)

Country Link
US (2) US9085807B2 (pl)
EP (2) EP2742951B1 (pl)
JP (1) JP5058804B2 (pl)
KR (2) KR101390072B1 (pl)
CN (1) CN101374550B (pl)
AU (1) AU2005284922B2 (pl)
CA (1) CA2577320C (pl)
ES (1) ES2610781T3 (pl)
PL (1) PL1794327T3 (pl)
PT (1) PT1794327T (pl)
WO (1) WO2006031870A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085807B2 (en) 2004-09-14 2015-07-21 Argos Therapeutics, Inc. Strain-independent amplification of pathogens and vaccines thereto
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
WO2009017743A2 (en) * 2007-07-30 2009-02-05 Argos Therapeutics, Inc. Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides
CA2711145A1 (en) * 2008-01-16 2009-07-23 Opal Therapeutics Pty Ltd Immunomodulating compositions and uses therefor
EP3257859B1 (en) 2009-02-26 2020-09-23 Gen-Probe Incorporated Assay for detection of human parvovirus nucleic acid
EP3052656B1 (en) * 2013-09-30 2018-12-12 President and Fellows of Harvard College Methods of determining polymorphisms
WO2015073773A1 (en) * 2013-11-14 2015-05-21 The General Hospital Corporation Suicide contrast agents targeting hiv reservoirs for theranostic erradication
AU2015218865B2 (en) * 2014-02-21 2021-06-10 Coimmune, Inc. TSCM cells and methods for use
US10682401B2 (en) 2015-05-19 2020-06-16 Morphogenesis, Inc. Multi-indication mRNA cancer immunotherapy
AU2016264363B2 (en) * 2015-05-19 2019-07-25 Tuhura Biosciences, Inc. Cancer vaccine comprising mRNA encoding a M-like-protein
EP3400309B1 (en) 2016-01-04 2025-03-19 Gen-Probe Incorporated Methods and compositions for detecting candida species
EP3414340B1 (en) * 2016-02-12 2023-08-09 CureVac SE Method for analyzing rna
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
US11779599B2 (en) 2017-11-07 2023-10-10 Coimmune, Inc. Methods and uses for dendritic cell therapy
BR112021000620A2 (pt) 2018-07-15 2021-04-20 Enochian BioPharma, Inc. métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer
BR112021024925A2 (pt) * 2019-06-10 2022-01-18 Andrea Savarino Método para a definição de uma vacina personalizada contra o hiv/aids

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5386022A (en) 1985-03-28 1995-01-31 Hoffman-La Roche Inc. Primes and probes for the amplification and detection of aids associated nucleic acids
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
DE07025195T1 (de) 1989-06-02 2009-05-07 Institut Pasteur Nukleotidsequenzen des Genoms von Retroviren des Typs HIV-1, HIV-2 und SIV und deren Anwendungen, insbesondere zur Amplifikation von Genomen dieser Retroviren und für die In-Vitro-Diagnostik von durch diese Viren ausgelösten Infektionen
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
US5427202A (en) 1994-03-11 1995-06-27 Behring; Melvin A. Apparatus and method for flushing transmission fluid
US5861161A (en) * 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
US5599662A (en) 1995-02-17 1997-02-04 Hoffmann-La Roche Inc. Oliconucleotide primers and probes for the detection of HIV-1
FR2731013B1 (fr) * 1995-02-27 1997-05-16 Inst Nat Sante Rech Med Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications
JP2000505802A (ja) 1996-02-12 2000-05-16 コブラ セラピューティクス リミテッド ワクチン接種の新規な方法、ならびにそのための、第１のエピトープをコードする核酸および第２のエピトープを含有するペプチドを含むワクチン
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
CA2222769C (en) 1997-01-17 2001-06-12 F. Hoffmann-La Roche Ag Primers for the detection of hiv-1
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US5962665A (en) 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
US6001558A (en) 1997-06-25 1999-12-14 Ortho Clinical Diagnostics, Inc. Amplification and detection of HIV-1 and/or HIV 2
WO1999016910A1 (en) 1997-09-26 1999-04-08 Visible Genetics Inc. Method and kit for evaluation of hiv mutations
CA2322750A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
US6379957B1 (en) 1998-09-21 2002-04-30 Leslie A. Johnston-Dow Methods for HIV sequencing and genotyping
WO2000044438A1 (en) 1999-01-28 2000-08-03 Cyto Pulse Sciences, Inc. Delivery of macromolecules into cells
CA2309313A1 (en) 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
ATE289630T1 (de) 1999-09-09 2005-03-15 Curevac Gmbh Transfer von mrnas unter verwendung von polykationischen verbindungen
EP1655305A3 (en) 2000-03-21 2006-09-13 Genzyme Corporation Therapeutic anti-cytomegalovirus compounds
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US20020164346A1 (en) 2001-02-14 2002-11-07 Nicolette Charles A. Altered peptide ligands
GB0111015D0 (en) 2001-05-04 2001-06-27 Norsk Hydro As Genetic material
US7547551B2 (en) 2001-06-21 2009-06-16 University Of Antwerp. Transfection of eukaryontic cells with linear polynucleotides by electroporation
US6852491B2 (en) 2001-09-04 2005-02-08 Abbott Laboratories Amplification and detection reagents for HIV-1
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US20040009194A1 (en) * 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
US20040081962A1 (en) 2002-10-23 2004-04-29 Caifu Chen Methods for synthesizing complementary DNA
KR100522526B1 (ko) 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
EP1578766B1 (en) 2002-12-03 2013-02-13 University of Massachusetts Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
JP2006518219A (ja) 2003-02-18 2006-08-10 マックスサイト インコーポレーティッド 電気穿孔法による細胞への抗原の負荷方法
DK2374900T3 (en) 2003-03-07 2016-10-17 Rubicon Genomics Inc Polynucleotides for amplification and analysis of the total genomic and total transcription libraries generated by a DNA polymerization
CN1882603A (zh) 2003-11-25 2006-12-20 阿哥斯医疗公司 mRNA转染的抗原呈递细胞
US9085807B2 (en) 2004-09-14 2015-07-21 Argos Therapeutics, Inc. Strain-independent amplification of pathogens and vaccines thereto
WO2009017743A2 (en) 2007-07-30 2009-02-05 Argos Therapeutics, Inc. Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides

Also Published As

Publication number Publication date
KR101390072B1 (ko) 2014-04-30
EP2742951A3 (en) 2014-07-30
CN101374550B (zh) 2013-05-15
WO2006031870A2 (en) 2006-03-23
JP2008513009A (ja) 2008-05-01
ES2610781T3 (es) 2017-05-03
JP5058804B2 (ja) 2012-10-24
KR20070058503A (ko) 2007-06-08
US9085807B2 (en) 2015-07-21
EP1794327A4 (en) 2011-02-23
KR101450497B1 (ko) 2014-10-13
EP1794327A2 (en) 2007-06-13
AU2005284922B2 (en) 2010-12-23
WO2006031870A9 (en) 2009-09-11
CA2577320C (en) 2019-08-13
CN101374550A (zh) 2009-02-25
CA2577320A1 (en) 2006-03-23
EP1794327B1 (en) 2016-11-30
US9879053B2 (en) 2018-01-30
PT1794327T (pt) 2017-01-24
WO2006031870A3 (en) 2008-09-25
US20080311155A1 (en) 2008-12-18
EP2742951A2 (en) 2014-06-18
US20150252083A1 (en) 2015-09-10
EP2742951B1 (en) 2016-02-03
KR20130072273A (ko) 2013-07-01
AU2005284922A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
PL1794327T3 (pl) Niezależna od szczepu amplifikacja patogenów i szczepionki przeciwko nim
IL184652A0 (en) Immune response modifier sterile formulations and methods
ZA200710173B (en) Tygecycline and methods of preparing 9-nitrominocycline
IL180947A0 (en) Vaccine for prevention and treatment of hiv infection
ZA200905626B (en) Adjuvants and methods of using them
IL189080A (en) Preserved benzimidazoles and preparation methods
IL182734A0 (en) 4-aminotetracyclines and methods of use thereof
IL184735A0 (en) Pharmaceutical formulations and methods of use
ZA200710974B (en) Inactivated chimeric vaccines and related methods of use
SI2144626T1 (sl) Cepivo proti tuberkulozi in postopek za njegovo uporabo
ZA200900203B (en) Adjuvants and methods of use
TWI369853B (en) Amplifier and class ab amplifier
EP1853632A4 (en) MODIFICATION OF AMINES AND ALCOHOLS
SI1951299T1 (sl) Cepiva proti influenci, ki vkljuäśujejo kombinacije adjuvantov iz delcev in imunopotenciatorjev
GB0423681D0 (en) Vaccine and nucleic acids
ZA200700507B (en) Identifying virally infected and vaccinated organisms
SI1812072T1 (sl) Formulacije benzotiazola in uporaba le-teh
GB0315160D0 (en) In vitro amplification of DNA
IL181228A0 (en) Vlp-antigen conjugates and their uses as vaccines
IL186277A0 (en) Dnt-maleate and methods of preparation thereof
GB0511722D0 (en) Live and subunit vaccines
EP1778281A4 (en) VACCINATION OF SKUNKS AND / OR MUNGOS AGAINST TOLLWUT
ZA200710950B (en) Lawsonia vaccine and methods of use thereof
TWI346557B (en) Adjuvant and vaccine includes the same
SG119341A1 (en) Novel bacterium and vaccine